Abstract 5850: AXA-042, a systemically administered TLR2/6 agonist, demonstrates innate immune engagement and Th1 polarization in patients with advanced solid tumors
Authors: Ben Tran, Sophia Frentzas, Charlotte Rose Lemech, Michael Millward, Daphne Day, Jayesh Desai, Ardian Latifi, Paul Wabnitz, Phil Kearney, Anna V. Galkin